Although the week's coverage has largely consisted of COVID-19 news, closer inspection finds it peppered with Mayo Clinic research on some other topics. We've collected a few of the news clips for ease of review. Read on for findings in cancer, deep vein thrombosis and Alzheimer's disease:
By Nichole Tucker, OncLive, 4/29/2020
A cell-free DNA (ctDNA) test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas (CCGA) study presented at the 2020 AACR Virtual Annual Meeting I.
Late cancer detection is one of the contributing factors toward advanced cancer diagnoses and cancer-related mortality. In particular, 30% of patients with breast cancer present with regional or distant metastases at diagnosis, as do roughly 55% of colorectal cancers and about 75% of lung and bronchial cancers.
“Many cancers are detected too late. The large percentage of breast, colorectal, and lung cancers are diagnosed simultaneously with metastatic disease. The detection of cancer prior to the development of metastatic disease can improve 5-year survival,” said David Thiel, MD, chair of the Department of Urology at Mayo Clinic.
By Lauren Dembeck, Ph.D., Cardiology Advisor, 4/28/2020
Treatment of upper extremity deep vein thrombosis (DVT) with apixaban or rivaroxaban appears to be as safe and effective as low molecular weight heparin (LMWH) and/or warfarin, according to study results published in the American Journal of Hematology. …
This study appears to be the first to compare clinical outcomes in upper extremity DVT for patients treated with apixaban or rivaroxaban compared with the traditional anticoagulation treatment of LMWH and/or warfarin. …
Patients with VTE who had enrolled in the Mayo Clinic VTE Registry from March 1, 2013, to December 31, 2019, were prospectively followed; clinical, demographic, and imaging data were collected.
— ALZFORUM, Series - AAT-AD/PD 2020 Conference: Advances in Alzheimer's and Parkinson's Therapies, 4/22/2020
Certain variants in the TREM2 gene more than triple a person’s risk of AD, seemingly by sapping the protective function this microglial receptor performs. According to findings presented at the virtual AAT-AD/PD meeting, held April 2 to 5, TREM2’s protective power falters as amyloidosis kicks into high gear.
Guojun Bu of the Mayo Clinic in Jacksonville, Florida, described what happened in a mouse model of amyloidosis when he switched on expression of human TREM2 at different stages of disease. Wild-type human TREM2 stemmed Aβ deposition, but only while plaques were in their infancy. It had no effect later on. In contrast, the R47H mutant never protected against plaques, and even exacerbated their growth. Together, the findings suggest that TREM2’s protective role is limited to early stages of Aβ deposition.
— ALZFORUM, 5/1/2020
In a virtual ceremony hosted by the American Brain Foundation on April 29, Potamkin Philanthropies awarded the 2020 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases to J. Paul Taylor from St. Jude Children’s Research Hospital, Memphis, Tennessee. …
With Rosa Rademakers at the Mayo Clinic, Jacksonville, Florida, he found that mutations in another RNA-binding protein, TIA1, increase the risk for ALD/FTD and these variants also promote liquid-liquid phase separation (Aug 2017 news).
For the collection of materials published on COVID-19 by Mayo Clinic, please visit the mini site.